|
시장보고서
상품코드
1786872
동반진단(CDx) 개발 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 서비스 유형별, 분석 수법별, 타겟 치료 영역별, 최종 사용자별, 지역별, 시장 예측(2025-2034년)Companion Diagnostics Development Market Size, Share, Trends, Industry Analysis Report By Type of Service, By Analytical Technique, By Target Therapeutic Area, By End User, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 동반진단(CDx) 개발 시장 규모는 2034년까지 17억 5,579만 달러에 이를 것으로 예측됩니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
동반진단(CDx) 개발 시장은 특정 치료제와 복잡한 관련 특수 진단 테스트의 생성과 생산을 중심으로 전개되고 있습니다. 이러한 검사는 어떤 환자가 특정 치료에서 가장 혜택을 받을 가능성이 있는지를 결정할 때 의료 전문가를 안내하는 중요한 정보를 제공하는 데 필수적입니다. 특정 바이오마커 및 유전적 특징을 확인함으로써 CDx는 개별 환자에 맞는 치료를 보장하여 부작용의 위험을 최소화하면서 약물의 안전성과 효능을 높일 수 있습니다. 이러한 의약품 및 진단제의 공동 개발 접근법은 Precision Medicine의 기초이며 헬스케어를 보다 개인화된 표적 치료로 향하게 합니다.
동반진단(CDx) 개발 시장은 맞춤형 의료를 향한 세계의 추진력과, 특히 암을 비롯한 질병의 복잡화에 의해 강력한 성장을 이루고 있습니다. 더 많은 표적 치료가 개발됨에 따라, 적격한 환자 집단을 확인하기 위한 CDx 수요는 증가의 길을 따라가고 있습니다. 분자생물학, 유전체학, 차세대 시퀀싱(NGS) 등의 분석기술의 개발도 이 분야의 기술 혁신에 박차를 가하고 있어 새로운 바이오마커의 발견과 보다 정교한 진단 툴의 개발을 가능하게 하고 있습니다. 규제기관은 CDx의 공동 개발 및 승인에 대한 지침을 제공함으로써 이 시장을 형성하는 데 중요한 역할을 하고 있으며, 이러한 진단 방법이 주류 의료 행위에 추가로 통합되어 있습니다.
동반진단(CDx) 개발 시장 보고서 하이라이트 :
서비스 유형별로, 임상 검증 분야는 2024년에 가장 큰 점유율을 차지했습니다. 이는 실제 환자 환경에서 진단제의 효능을 입증하는데 필수적인 역할을 하기 때문입니다. 견고한 임상 검증은 규제 당국의 승인에 필수적이며 검사가 특정 약물에 대한 환자의 반응을 정확하게 예측할 수 있도록 보장합니다.
분석 기법별로, 중합효소 연쇄반응(PCR) 분야는 2024년에 가장 큰 점유율을 차지했습니다. 이는 신뢰성이 높고 비용 효율성이 높으며, 임상 실험실에서의 활용도가 증명되기 때문입니다. 유전자 표적의 검출에 있어서 높은 감도와 특이성에 의해 표적 치료의 지침이 되는 바이오마커를 동정하기 위한 기본 기술이 되고 있습니다.
표적 치료 영역별로 2024년 종양 질환이 가장 큰 점유율을 차지했습니다. 이것은 주로 다양한 암 세계의 높은 유병률 및 암 치료에서 맞춤형 의료의 채용 증가에 의한 것입니다. 동반진단은 특정 암 치료에 가장 잘 반응하는 환자를 선택하는 데 필수적입니다.
최종 사용자별로는 2024년 업계 기업 부문이 창약에 대한 대규모 투자와 새로운 치료제 및 CDx를 공동 개발하는 고유의 필요성으로 인해 큰 점유율을 차지했습니다. 업계 각사의 광범위한 리소스 및 세계 상업 네트워크는 복잡한 규제 요건에 대응할 수 있어 CDx 채용을 촉진합니다.
지역별로는 북미가 2024년 동반진단 시장에서 가장 큰 점유율을 차지하고 있으며, 그 이유로는 선진적인 헬스케어 인프라, 높은 의료비, 새로운 진단 기술의 신속한 도입을 촉구하는 지원적인 규제 환경을 들 수 있습니다.
동반진단(CDx) 개발 시장은 F. Hoffmann-La Roche Ltd., QIAGEN NV, Agilent Technologies, Inc., Abbott Laboratories, Illumina, Inc., Myriad Genetics, Inc., Sysmex Corporation, BioMerieux SA, Thermo Fisher Scientific Inc., Labcorp, Quest Diagnostics, Guardant Health, Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 동반진단(CDx) 개발 시장 인사이트
- 시장 현황
- 동반진단(CDx) 개발 시장 역학
- 성장 촉진요인 및 기회
- 맞춤형 의료 도입 확대
- 암 발생률 상승
- 성장 억제요인 및 과제
- 복잡하고 장기적인 공동 개발 및 승인 프로세스
- 성장 촉진요인 및 기회
- PESTEL 분석
- 동반진단(CDx) 개발 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 동반진단(CDx) 개발 시장 : 서비스 유형별
- 주요 조사 결과
- 서문
- 실현 가능성 조사
- 어세이 개발
- 분석 검증
- 임상 검증
- 제조업
제6장 세계의 동반진단(CDx) 개발 시장 : 분석 기술별
- 주요 조사 결과
- 서문
- NGS
- PCR
- IHC
- 플로우 사이토메트리
- 기타
제7장 세계의 동반진단(CDx) 개발 시장 : 타겟 치료 영역별
- 주요 조사 결과
- 서문
- 종양성 질환
- 비종양성 질환
제8장 세계의 동반진단(CDx) 개발 시장 : 최종 사용자별
- 주요 조사 결과
- 서문
- 업계 기업
- 업계외 기업
제9장 세계의 동반진단(CDx) 개발 시장 : 지역별
- 주요 조사 결과
- 서문
- 동반진단(CDx) 개발 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 서비스 유형별(2020-2034년)
- 북미 : 분석 기술별(2020-2034년)
- 북미 : 타겟 치료 영역별(2020-2034년)
- 북미 : 최종 사용자별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 서비스 유형별(2020-2034년)
- 유럽 : 분석 기술별(2020-2034년)
- 유럽 : 타겟 치료 영역별(2020-2034년)
- 유럽 : 최종 사용자별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 서비스 유형별(2020-2034년)
- 아시아태평양 : 분석 기술별(2020-2034년)
- 아시아태평양 : 타겟 치료 영역별(2020-2034년)
- 아시아태평양 : 최종 사용자별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 서비스 유형별(2020-2034년)
- 중동 및 아프리카 : 분석 기술별(2020-2034년)
- 중동 및 아프리카 : 타겟 치료 영역별(2020-2034년)
- 중동 및 아프리카 : 최종 사용자별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 서비스 유형별(2020-2034년)
- 라틴아메리카 : 분석 기술별(2020-2034년)
- 라틴아메리카 : 타겟 치료 영역별(2020-2034년)
- 라틴아메리카 : 최종 사용자별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴, 협업, 합의 및 공개
제11장 기업 프로파일
- Abbott Laboratories
- Agilent Technologies, Inc.
- BioMerieux SA
- F. Hoffmann-La Roche Ltd.
- Guardant Health, Inc.
- Illumina, Inc.
- Labcorp
- Myriad Genetics, Inc.
- QIAGEN NV
- Quest Diagnostics
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
The global companion diagnostics (CDx) development market size is expected to reach USD 1,755.79 million by 2034, according to a new study by Polaris Market Research. The report "Companion Diagnostics (Cdx) Development Market Size, Share, Trends, Industry Analysis Report By Type of Service (Feasibility Studies, Assay Development), By Analytical Technique, By Target Therapeutic Area, By End User, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The companion diagnostics (CDx) development market revolves around the creation and production of specialized diagnostic tests that are intricately linked with specific therapeutic drugs. These tests are vital for providing crucial information that guides healthcare professionals in determining which patients are most likely to benefit from a particular treatment. By identifying specific biomarkers or genetic characteristics, CDx ensures that treatments are tailored to individual patients, thereby enhancing both the safety and effectiveness of medications while minimizing the risk of adverse reactions. This co-development approach between a drug and its diagnostic is a cornerstone of precision medicine, moving healthcare toward more personalized and targeted interventions.
The companion diagnostics development market is experiencing strong growth, driven by a global push toward personalized medicine and the increasing complexity of diseases, especially cancer. As more targeted therapies are developed, the demand for CDx to identify eligible patient populations continues to rise. Advancements in molecular biology, genomics, and analytical techniques such as next-generation sequencing (NGS) are also fueling innovation in this sector, allowing for the discovery of new biomarkers and the development of more sophisticated diagnostic tools. Regulatory agencies play a key role in shaping this market by providing guidelines for the co-development and approval of CDx, further integrating these diagnostics into mainstream medical practice.
Companion Diagnostics Development Market Report Highlights:
By type of service, the clinical validation segment held the largest share in 2024 due to its essential role in demonstrating a diagnostic's effectiveness in real-world patient settings. Robust clinical validation is critical for regulatory approval, ensuring the test accurately predicts patient response to a specific drug.
By analytical technique, the polymerase chain reaction (PCR) segment held the largest share in 2024 owing to its proven reliability, cost-effectiveness, and widespread use in clinical labs. Its high sensitivity and specificity in detecting genetic targets make it a fundamental technology for identifying biomarkers that guide targeted therapies.
By target therapeutic area, the oncological disorders segment held the largest share in 2024, primarily driven by the high global prevalence of various cancers and the increasing adoption of personalized medicine in cancer treatment. Companion diagnostics are vital for selecting patients who will best respond to specific cancer therapies.
By end user, the industry players segment held a larger share in 2024 due to their significant investments in drug discovery and their inherent need to co-develop CDx alongside new therapeutics. Their extensive resources and global commercial networks enable them to navigate complex regulatory requirements and drive CDx adoption.
By region, North America held the largest share of the global companion diagnostics market in 2024, benefiting from its advanced healthcare infrastructure, high healthcare spending, and a supportive regulatory environment that encourages the rapid adoption of new diagnostic technologies.
The companion diagnostics development market includes active players such as F. Hoffmann-La Roche Ltd.; QIAGEN N.V.; Agilent Technologies, Inc.; Abbott Laboratories; Illumina, Inc.; Myriad Genetics, Inc.; Sysmex Corporation; BioMerieux SA; Thermo Fisher Scientific Inc.; Labcorp; Quest Diagnostics; and Guardant Health, Inc.
Polaris Market Research has segmented the CDx development market report on the basis of type of service, analytical technique, target therapeutic area, end user, and region:
By Type of Service Outlook (Revenue - USD Million, 2020-2034)
Feasibility Studies
Assay Development
Analytical Validation
Clinical Validation
Manufacturing
By Analytical Technique Outlook (Revenue - USD Million, 2020-2034)
NGS
PCR
IHC
Flow Cytometry
Others
By Target Therapeutic Area Outlook (Revenue - USD Million, 2020-2034)
Oncological Disorders
Non-oncological Disorders
By End User Outlook (Revenue - USD Million, 2020-2034)
Industry Players
Non-Industry Players
By Regional Outlook (Revenue - USD Million, 2020-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Companion Diagnostics (Cdx) Development Market Insights
- 4.1. Companion Diagnostics (Cdx) Development Market - Market Snapshot
- 4.2. Companion Diagnostics (Cdx) Development Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing Adoption of Personalized Medicine
- 4.2.1.2. Rising Incidence of Cancer
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Complex and lengthy co-development and approval processes
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Companion Diagnostics (Cdx) Development Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Companion Diagnostics (Cdx) Development Market, by Type of Service
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 5.3. Feasibility Studies
- 5.3.1. Global Companion Diagnostics (Cdx) Development Market, by Feasibility Studies, by Region, 2020-2034 (USD Million)
- 5.4. Assay Development
- 5.4.1. Global Companion Diagnostics (Cdx) Development Market, by Assay Development, by Region, 2020-2034 (USD Million)
- 5.5. Analytical Validation
- 5.5.1. Global Companion Diagnostics (Cdx) Development Market, by Analytical Validation, by Region, 2020-2034 (USD Million)
- 5.6. Clinical Validation
- 5.6.1. Global Companion Diagnostics (Cdx) Development Market, by Clinical Validation, by Region, 2020-2034 (USD Million)
- 5.7. Manufacturing
- 5.7.1. Global Companion Diagnostics (Cdx) Development Market, by Manufacturing, by Region, 2020-2034 (USD Million)
6. Global Companion Diagnostics (Cdx) Development Market, by Analytical Technique
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 6.3. NGS
- 6.3.1. Global Companion Diagnostics (Cdx) Development Market, by NGS, by Region, 2020-2034 (USD Million)
- 6.4. PCR
- 6.4.1. Global Companion Diagnostics (Cdx) Development Market, by PCR, by Region, 2020-2034 (USD Million)
- 6.5. IHC
- 6.5.1. Global Companion Diagnostics (Cdx) Development Market, by IHC, by Region, 2020-2034 (USD Million)
- 6.6. Flow Cytometry
- 6.6.1. Global Companion Diagnostics (Cdx) Development Market, by Flow Cytometry, by Region, 2020-2034 (USD Million)
- 6.7. Others
- 6.7.1. Global Companion Diagnostics (Cdx) Development Market, by Others, by Region, 2020-2034 (USD Million)
7. Global Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 7.3. Oncological Disorders
- 7.3.1. Global Companion Diagnostics (Cdx) Development Market, by Oncological Disorders, by Region, 2020-2034 (USD Million)
- 7.4. Non-oncological Disorders
- 7.4.1. Global Companion Diagnostics (Cdx) Development Market, by Non-oncological Disorders, by Region, 2020-2034 (USD Million)
8. Global Companion Diagnostics (Cdx) Development Market, by End User
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 8.3. Industry Players
- 8.3.1. Global Companion Diagnostics (Cdx) Development Market, by Industry Players, by Region, 2020-2034 (USD Million)
- 8.4. Non-Industry Players
- 8.4.1. Global Companion Diagnostics (Cdx) Development Market, by Non-Industry Players, by Region, 2020-2034 (USD Million)
9. Global Companion Diagnostics (Cdx) Development Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Companion Diagnostics (Cdx) Development Market Assessment, By Geography, 2020-2034 (USD Million)
- 9.3. Companion Diagnostics (Cdx) Development Market - North America
- 9.3.1. North America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.3.2. North America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.3.3. North America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.3.4. North America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.3.5. Companion Diagnostics (Cdx) Development Market - US
- 9.3.5.1. US: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.3.5.2. US: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.3.5.3. US: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.3.5.4. US: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.3.6. Companion Diagnostics (Cdx) Development Market - Canada
- 9.3.6.1. Canada: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.3.6.2. Canada: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.3.6.3. Canada: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.3.6.4. Canada: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4. Companion Diagnostics (Cdx) Development Market - Europe
- 9.4.1. Europe: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.2. Europe: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.3. Europe: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.4. Europe: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.5. Companion Diagnostics (Cdx) Development Market - UK
- 9.4.5.1. UK: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.5.2. UK: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.5.3. UK: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.5.4. UK: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.6. Companion Diagnostics (Cdx) Development Market - France
- 9.4.6.1. France: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.6.2. France: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.6.3. France: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.6.4. France: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.7. Companion Diagnostics (Cdx) Development Market - Germany
- 9.4.7.1. Germany: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.7.2. Germany: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.7.3. Germany: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.7.4. Germany: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.8. Companion Diagnostics (Cdx) Development Market - Italy
- 9.4.8.1. Italy: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.8.2. Italy: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.8.3. Italy: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.8.4. Italy: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.9. Companion Diagnostics (Cdx) Development Market - Spain
- 9.4.9.1. Spain: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.9.2. Spain: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.9.3. Spain: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.9.4. Spain: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.10. Companion Diagnostics (Cdx) Development Market - Netherlands
- 9.4.10.1. Netherlands: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.10.2. Netherlands: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.10.3. Netherlands: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.10.4. Netherlands: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.11. Companion Diagnostics (Cdx) Development Market - Russia
- 9.4.11.1. Russia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.11.2. Russia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.11.3. Russia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.11.4. Russia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.4.12. Companion Diagnostics (Cdx) Development Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.4.12.2. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.4.12.3. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.4.12.4. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5. Companion Diagnostics (Cdx) Development Market - Asia Pacific
- 9.5.1. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.2. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.3. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.4. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.5. Companion Diagnostics (Cdx) Development Market - China
- 9.5.5.1. China: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.5.2. China: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.5.3. China: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.5.4. China: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.6. Companion Diagnostics (Cdx) Development Market - India
- 9.5.6.1. India: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.6.2. India: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.6.3. India: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.6.4. India: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.7. Companion Diagnostics (Cdx) Development Market - Malaysia
- 9.5.7.1. Malaysia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.7.2. Malaysia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.7.3. Malaysia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.7.4. Malaysia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.8. Companion Diagnostics (Cdx) Development Market - Japan
- 9.5.8.1. Japan: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.8.2. Japan: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.8.3. Japan: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.8.4. Japan: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.9. Companion Diagnostics (Cdx) Development Market - Indonesia
- 9.5.9.1. Indonesia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.9.2. Indonesia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.9.3. Indonesia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.9.4. Indonesia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.10. Companion Diagnostics (Cdx) Development Market - South Korea
- 9.5.10.1. South Korea: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.10.2. South Korea: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.10.3. South Korea: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.10.4. South Korea: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.11. Companion Diagnostics (Cdx) Development Market - Australia
- 9.5.11.1. Australia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.11.2. Australia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.11.3. Australia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.11.4. Australia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.5.12. Companion Diagnostics (Cdx) Development Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.5.12.2. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.5.12.3. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.5.12.4. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.6. Companion Diagnostics (Cdx) Development Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.6.2. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.6.3. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.6.4. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.6.5. Companion Diagnostics (Cdx) Development Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.6.5.2. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.6.5.3. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.6.5.4. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.6.6. Companion Diagnostics (Cdx) Development Market - UAE
- 9.6.6.1. UAE: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.6.6.2. UAE: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.6.6.3. UAE: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.6.6.4. UAE: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.6.7. Companion Diagnostics (Cdx) Development Market - Israel
- 9.6.7.1. Israel: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.6.7.2. Israel: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.6.7.3. Israel: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.6.7.4. Israel: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.6.8. Companion Diagnostics (Cdx) Development Market - South Africa
- 9.6.8.1. South Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.6.8.2. South Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.6.8.3. South Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.6.8.4. South Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.6.9. Companion Diagnostics (Cdx) Development Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.6.9.2. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.6.9.3. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.6.9.4. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.7. Companion Diagnostics (Cdx) Development Market - Latin America
- 9.7.1. Latin America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.7.2. Latin America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.7.3. Latin America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.7.4. Latin America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.7.5. Companion Diagnostics (Cdx) Development Market - Mexico
- 9.7.5.1. Mexico: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.7.5.2. Mexico: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.7.5.3. Mexico: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.7.5.4. Mexico: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.7.6. Companion Diagnostics (Cdx) Development Market - Brazil
- 9.7.6.1. Brazil: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.7.6.2. Brazil: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.7.6.3. Brazil: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.7.6.4. Brazil: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.7.7. Companion Diagnostics (Cdx) Development Market - Argentina
- 9.7.7.1. Argentina: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.7.7.2. Argentina: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.7.7.3. Argentina: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.7.7.4. Argentina: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
- 9.7.8. Companion Diagnostics (Cdx) Development Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
- 9.7.8.2. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
- 9.7.8.3. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
- 9.7.8.4. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Abbott Laboratories
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Agilent Technologies, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. BioMerieux SA
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. F. Hoffmann-La Roche Ltd.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Guardant Health, Inc.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Illumina, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Labcorp
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Myriad Genetics, Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. QIAGEN N.V.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Quest Diagnostics
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Sysmex Corporation
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Thermo Fisher Scientific Inc.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
